Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

23andMe FDA Approval Clears Way for More Sequencing-Based Tests

By Drug Discovery Trends Editor | March 17, 2015

​Kalorama information suggests that the FDA approval of a rare gene test from Mountain View, Calif.-based personal genetics company 23andMe will open the way for more genetic tests sold to consumers or prescribed by doctors that use next-generation sequencing technology.  A Feb. 19th approval letter from the FDA has cleared a test for a gene that can cause a rare disorder called Bloom Syndrome, which causes short stature and a heightened risk of cancer.  Most importantly the letter hints at a reduced review process for similar tests.  In the healthcare market research firm’s report, Next Generation Sequencing 2015, 23andme and several other companies and sequencing-based tests like theirs are discussed.   
 
Kalorama notes that the new policy, coming just 15 months after 23andMe received an FDA warning letter, represents the agency’s attempt to adjust to the demand for applications for sequencing technology while still maintaining a regulatory role for advanced diagnostic tests.  
 
“The reversal of policy was probably inevitable, given that the agency’s actions if continued would diverge from the trend towards personalized medicine, patient-centered medicine, and the sharing of important medical information with patients,” said Bruce Carlson, Publisher of Kalorama Information.  “A balance has been struck here.”  
 
Kalorama notes that President Obama’s personalized medicine program as part of his 2015 budget proposal, and the recent approval of MiSeqDx hinted that the US government was seeking a friendlier approach towards any test that might help consumers identify risks and aid the healthcare system in diagnosis and prevention.  The approval of the particular test (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM435003) is aided by on the certainty involving this gene in a prenatal test. It’s a rare disorder but more common where both parents are of Ashkenazi Jewish descent.   If both parents have the a version of the gene, their child will have the disorder.  
 
“Had this been the only test affected, it still would have been a positive news story for the next generation sequencing and IVD industries, but the FDA’s letter also contained this note, hinting at a broader change in regulation of genetic tests,” Carlson said.  
 
The FDA approval letter noted that:  “Along with this authorization, the FDA is also classifying carrier screening tests as class II. In addition, the FDA intends to exempt these devices from FDA premarket review. The agency plans to issue a notice that announces the intent to exempt these tests and that provides a 30-day period for public comment. This action creates the least burdensome regulatory path for autosomal recessive carrier screening tests with similar uses to enter the market.” 
 
A testmaker now has to notify the FDA and be sure that its diagnostic met certain requirements.  23andMe  had to demonstrate that the test was accurate, could be validated across laboratories, and that the report of test results were comprehensible to individuals not previously familiar with the DNA test kit.
 
Source: Kalorama

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE